Match!
Christopher McQuinn
Ohio State University
CancerImmunologyChemotherapyImmunotherapyMedicine
6Publications
3H-index
85Citations
What is this?
Publications 7
Newest
#1Michael B. Ware (Emory University)H-Index: 1
#2Christopher McQuinn (OSU: Ohio State University)H-Index: 3
Last. Jacob S. Bowers (MUSC: Medical University of South Carolina)H-Index: 8
view all 17 authors...
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is exceptionally resistant to immune checkpoint inhibition (ICI). We previously reported that elevated systemic interleukin-6 (IL-6) and increased numbers of T cells positive for circulating cytotoxic T-lymphocyte-associated protein 4 (CTLA 4) correlate with worse overall survival in patients with PDAC. We postulated that combined blockade of IL-6 and CTLA-4 would significantly enhance anti-tumor immune responses to PDAC. Dual blockade of IL-6 an...
Source
#1Michael B. Ware (Emory University)H-Index: 1
#2Christopher McQuinn (OSU: Ohio State University)H-Index: 3
Last. Gregory B. Lesinski (Emory University)H-Index: 29
view all 11 authors...
Immune checkpoint blockade therapy has shown promise in many cancers. However, pancreatic ductal adenocarcinoma (PDAC) has proven refractory to most targeted and immune-based therapies. Previous research by our group and others demonstrated immune suppression in PDAC driven by activated fibroblasts, known as pancreatic stellate cells (PSCs). Specifically, our lab has demonstrated expansion of myeloid-derived suppressor cells (MDSCs) by PSCs in an interleukin-6 (IL-6) and STAT3 dependent manner (...
Source
#1Robert WesolowskiH-Index: 13
#2Zaibo LiH-Index: 10
Last. William E. CarsonH-Index: 26
view all 11 authors...
Source
#1Thomas A. Mace (OSU: Ohio State University)H-Index: 14
#2Reena Shakya (OSU: Ohio State University)H-Index: 15
Last. Gregory B. Lesinski (Emory University)H-Index: 29
view all 17 authors...
Objective Limited efficacy of immune checkpoint inhibitors in pancreatic ductal adenocarcinoma (PDAC) has prompted investigation into combination therapy. We hypothesised that interleukin 6 (IL-6) blockade would modulate immunological features of PDAC and enhance the efficacy of anti-programmed death-1-ligand 1 (PD-L1) checkpoint inhibitor therapy. Design Transcription profiles and IL-6 secretion from primary patient-derived pancreatic stellate cells (PSCs) were analyzed via Nanostring and immun...
69 CitationsSource
#1Andrew Stiff (OSU: Ohio State University)H-Index: 9
#2Christopher McQuinn (OSU: Ohio State University)H-Index: 3
Last. William E. Carson (The Ohio State University Wexner Medical Center)H-Index: 43
view all 12 authors...
e12126Background: Even with neo-adjuvant chemotherapy (NAC) many breast cancer (BC) patients (pts) relapse, especially triple negative pts. The incorporation of checkpoint inhibitors into NAC for BC is being tested in clinical trials. How NAC affects checkpoint receptor expression is not known. Such information could aid in the rational selection of checkpoints to target during NAC. We sought to characterize changes in the frequency of circulating CD4 and CD8 T cells expressing PD1, CTLA4, LAG3,...
Source
#1Casey Ager (University of Texas MD Anderson Cancer Center)H-Index: 5
#2Matthew J. Reilley (University of Texas MD Anderson Cancer Center)H-Index: 5
Last. Sumanta K. Pal (City of Hope National Medical Center)H-Index: 43
view all 1541 authors...
About this supplement These abstracts have been published as part of Journal for ImmunoTherapy of Cancer Volume 4 Suppl 1, 2016. The full contents of the supplement are available online at http://jitc.biomedcentral.com/articles/supplements/volume-4-supplement-1. Please note that this is part 1 of 2.
11 CitationsSource
#1Christopher McQuinn (OSU: Ohio State University)H-Index: 3
#2Thomas A. Mace (OSU: Ohio State University)H-Index: 14
Last. Gregory B. Lesinski (OSU: Ohio State University)H-Index: 29
view all 11 authors...
One hallmark of pancreatic ductal adenocarcinoma (PDAC) is the dense stroma that includes activated myofibroblast-like cells termed ‘pancreatic stellate cells’ (PSC). We hypothesized that antitumor immunity is restrained by PSC, and that key pathways can be identified to augment efficacy of immunotherapy. To gain insight into the most relevant soluble factors and pathways, primary PSC (n=10) were isolated from PDAC patients. A normal human pancreatic fibroblast (HPF) cell line was used as a cont...
1